Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | Director | May 20, 2026 | May 22, 2026 |
| INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802 | Director | June 16, 2022 | June 16, 2022 |
| Zai Lab LtdZLAB · Entity 4271 | Director | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date May 20, 2026 · Filed May 22, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.98 · Expires 2036-05-20 | Direct | 11,538 |
Reported balance
After 2026-05-20 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 11,538 · Balance 11,538 F1: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 5,409 |
Reported balance
After 2026-05-20 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 5,409 · Balance 5,409 F3: Each restricted stock unit represents a contingent right to receive one ordinary share. F1: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
F2: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above.
F3: Each restricted stock unit represents a contingent right to receive one ordinary share.
INFINITY PHARMACEUTICALS, INC.
Report date June 16, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2032-06-16 | Direct | 45,000 |
Reported balance
After 2022-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-16 · Grant · Acquired 45,000 · Balance 45,000 F1: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.
Zai Lab Ltd
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 80,737 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Purchase · Acquired 1,736 · Balance 80,737 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Neon Therapeutics, Inc.
Report date May 06, 2020 · Filed May 06, 2020
Section 16 reporting ended · disclosed 2020-05-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 1
1 source rowRow 1 · 2020-05-06 · Disposition to issuer · Disposed 210,410 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 159,584 restricted stock units (each, an "RSU") held by the Reporting Person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.20 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-06 · Disposition to issuer · Disposed 58,005 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.13 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-06 · Disposition to issuer · Disposed 105,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-05-06 · Disposition to issuer · Disposed 155,373 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 159,584 restricted stock units (each, an "RSU") held by the Reporting Person.
F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").
F3: Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 6, 2026 20:14 UTC | Zai Lab Ltd ZLAB · Entity 4271 | PurchaseAmerican Depositary Shares | 1,736 | $19.05 | $33,070.80 |
DisclosureSEC source: 0000905148-26-003169 · form4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,737 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2025. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:08 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 22,371 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003032 · form4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,001 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:59 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000084 · form4.xml · derivative · entry 5 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · derivative.exercise_date: This award is fully vested in accordance with its terms. F4 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:59 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,475 | $36.95 | $54,501.25 |
DisclosureSEC source: 0001520262-26-000084 · form4.xml · nonDerivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,751 Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:59 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000084 · form4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:59 UTC Amendment | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001520262-26-000087 · form4a.xml · derivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,409 Underlying: Ordinary Shares · 5,409 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2 · derivative.exercise_date: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above. F1 · derivative.expiration_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2 · derivative.expiration_date: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:59 UTC Amendment | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 11,538 | $0.00 Strike: $36.98 | $0.00 |
DisclosureSEC source: 0001520262-26-000087 · form4a.xml · derivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,538 Underlying: Ordinary Shares · 11,538 shares Expires 2036-05-20 F1 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2 · derivative.exercise_date: This amendment is being filed to reflect the vesting terms applicable to this award, which were reported incorrectly on the original Form 4. The correct vesting schedule is set forth in Footnote 1 above. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:59 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001520262-26-000084 · form4.xml · derivative · entry 4 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,409 Underlying: Ordinary Shares · 5,409 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2027. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2027. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:59 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 11,538 | $0.00 Strike: $36.98 | $0.00 |
DisclosureSEC source: 0001520262-26-000084 · form4.xml · derivative · entry 3 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,538 Underlying: Ordinary Shares · 11,538 shares Expires 2036-05-20 F2 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/20/2027. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 20:05 UTC | Zai Lab Ltd ZLAB · Entity 4271 | PurchaseAmerican Depositary Shares | 1,731 | $18.91 | $32,733.21 |
DisclosureSEC source: 0000905148-26-001398 · form4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,630 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2025. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:11 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 10,831 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002217 · form4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,899 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 18, 2026, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:29 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 8,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-016198 · form4.xml · derivative · entry 3 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:29 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,924 | $30.61 | $58,893.64 |
DisclosureSEC source: 0001127602-25-016198 · form4.xml · nonDerivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,084 Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:29 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 8,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-016198 · form4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:56 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 6,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015539 · form4.xml · derivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,142 Underlying: Ordinary Shares · 6,142 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:56 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 13,474 | $0.00 Strike: $30.53 | $0.00 |
DisclosureSEC source: 0001127602-25-015539 · form4.xml · derivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,474 Underlying: Ordinary Shares · 13,474 shares Expires 2035-05-21 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/21/2026. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 21:21 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleAmerican Depositary Shares | 2,500 | $35.07 | $87,675.00 |
DisclosureSEC source: 0000905148-25-000873 · form4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,068 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2024. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:13 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleAmerican Depositary Shares | 2,500 | $19.50 | $48,750.00 |
DisclosureSEC source: 0000905148-24-002519 · form4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,568 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2024. Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 20:55 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-019594 · form4.xml · derivative · entry 3 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 20:55 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,465 | $24.10 | $35,306.50 |
DisclosureSEC source: 0001127602-24-019594 · form4.xml · nonDerivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,995 Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 20:55 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-019594 · form4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 21,253 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001753 · form4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,068 F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 18, 2025, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:53 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 17,492 | $0.00 Strike: $23.40 | $0.00 |
DisclosureSEC source: 0001127602-24-017725 · form4.xml · derivative · entry 10 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,492 Underlying: Ordinary Shares · 17,492 shares Expires 2034-05-31 F7 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/31/2025. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:53 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 8,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017725 · form4.xml · derivative · entry 9 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,013 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F6 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. F6 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:53 UTC | Alkermes plc. ALKS · Entity 2392 | OtherRestricted Stock Unit Award · Derivative | 119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-017725 · form4.xml · derivative · entry 8 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,104 Underlying: Ordinary Shares · 119 shares Expires not disclosed F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:53 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 254 | $30.72 Strike: $30.72 | $7,802.88 |
DisclosureSEC source: 0001127602-24-017725 · form4.xml · derivative · entry 7 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,986 Underlying: Ordinary Shares · 254 shares Expires 2033-06-29 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:53 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 231 | $30.86 Strike: $30.86 | $7,128.66 |
DisclosureSEC source: 0001127602-24-017725 · form4.xml · derivative · entry 6 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,785 Underlying: Ordinary Shares · 231 shares Expires 2032-07-07 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:53 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 313 | $24.24 Strike: $24.24 | $7,587.12 |
DisclosureSEC source: 0001127602-24-017725 · form4.xml · derivative · entry 5 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,990 Underlying: Ordinary Shares · 313 shares Expires 2031-06-14 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:53 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 230 | $18.45 Strike: $18.45 | $4,243.50 |
DisclosureSEC source: 0001127602-24-017725 · form4.xml · derivative · entry 4 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,739 Underlying: Ordinary Shares · 230 shares Expires 2030-12-02 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:53 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 256 | $16.52 Strike: $16.52 | $4,229.12 |
DisclosureSEC source: 0001127602-24-017725 · form4.xml · derivative · entry 3 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,079 Underlying: Ordinary Shares · 256 shares Expires 2030-05-20 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:53 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 224 | $20.81 Strike: $20.81 | $4,661.44 |
DisclosureSEC source: 0001127602-24-017725 · form4.xml · derivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,424 Underlying: Ordinary Shares · 224 shares Expires 2029-12-04 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 20:53 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 1,236 | $20.81 Strike: $20.81 | $25,721.16 |
DisclosureSEC source: 0001127602-24-017725 · form4.xml · derivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,036 Underlying: Ordinary Shares · 1,236 shares Expires 2029-12-04 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:30 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 5,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020547 · form4.xml · derivative · entry 3 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,957 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:30 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,430 | $29.88 | $42,728.40 |
DisclosureSEC source: 0001127602-23-020547 · form4.xml · nonDerivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,356 Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:30 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020547 · form4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:33 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019628 · form4.xml · derivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,985 Underlying: Ordinary Shares · 5,985 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:33 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 12,732 | $0.00 Strike: $31.33 | $0.00 |
DisclosureSEC source: 0001127602-23-019628 · form4.xml · derivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,732 Underlying: Ordinary Shares · 12,732 shares Expires 2033-06-29 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:05 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 18,903 | $26.45 | $499,984.35 |
DisclosureSEC source: 0000950170-23-031095 · ownership.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,815 F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:19 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 11,554 | $0.00 Strike: $31.48 | $0.00 |
DisclosureSEC source: 0001127602-22-019127 · form4.xml · derivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,554 Underlying: Ordinary Shares · 11,554 shares Expires 2032-07-07 F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 7/7/2023. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:19 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-019127 · form4.xml · derivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,957 Underlying: Ordinary Shares · 5,957 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 7/7/2023. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 7/7/2023. Read SEC document |
| June 16, 2022 Filed Jun 16, 2022 20:43 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option(right to buy) · Derivative | 45,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001140361-22-023319 · form4.xml · derivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:57 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 7,585 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017637 · form4.xml · derivative · entry 3 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,585 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:57 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 695 | $27.19 | $18,897.05 |
DisclosureSEC source: 0001127602-22-017637 · form4.xml · nonDerivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,829 Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:57 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 7,585 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017637 · form4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| December 02, 2021 Filed Dec 4, 2021 02:24 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 5,578 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-030302 · form4.xml · derivative · entry 3 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,578 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| December 02, 2021 Filed Dec 4, 2021 02:24 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,339 | $22.11 | $29,605.29 |
DisclosureSEC source: 0001127602-21-030302 · form4.xml · nonDerivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,939 Read SEC document |
| December 02, 2021 Filed Dec 4, 2021 02:24 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,578 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-030302 · form4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 12:40 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantOrdinary Shares | 8,912 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045487 · doc4.xml · nonDerivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,912 Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:26 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 7,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020043 · form4.xml · derivative · entry 2 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,585 Underlying: Ordinary Shares · 7,585 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/14/2022. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/14/2022. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:26 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 15,677 | $0.00 Strike: $24.72 | $0.00 |
DisclosureSEC source: 0001127602-21-020043 · form4.xml · derivative · entry 1 GAYNOR RICHARD · CIK 0001741284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,677 Underlying: Ordinary Shares · 15,677 shares Expires 2031-06-14 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/14/2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.